Kazuhiro Takei

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

Kazuhiro Takei, Tetsuo Yamazaki, Umihiko Sawada et al. · Leukemia Research · 2005 · 90 citations

Hematological Malignancy, Lymphoid Neoplasia, Cd59 Expression +9

Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy.

Naoto Shikama, I Izuno, Masahiko Oguchi et al. · Radiology · 1997 · 46 citations

Treatment of High-Risk Peripheral T-Cell Lymphomas other than Anaplastic Large-Cell Lymphoma with a Dose-Intensified CHOP Regimen Followed by High-Dose Chemotherapy

Tetsuo Yamazaki, Umihiko Sawada, Yoshimasa Kura et al. · Acta Haematologica · 2006 · 16 citations

Cell Therapy, Secondary Leukemia, Dose-intensified Double-chop Regimen +19

An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

Katsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi et al. · International Journal of Hematology · 2011 · 11 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +6

The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients

Akira Horikoshi, Kazuhiro Takei, Yoshifumi Hosokawa et al. · International Journal of Hematology · 2008 · 10 citations

Geriatrics, Medicine, Oral Cytarabine Ocfosfate +4